Confirm that the diagnosis is 5q SMA before using a 5q-SMA treatment pathway
Most current disease-modifying SMA therapies target the biology of SMN1-related 5q SMA. A German second opinion should therefore start with the molecular report, not only with a clinical label of motor-neuron disease or muscle weakness.
- SMN1 deletion or pathogenic-variant report
- SMN2 copy number when available
- Age at symptom onset and best-ever motor milestone
- Current ambulatory, sitting and upper-limb function
- Respiratory and swallowing status
- Previous nusinersen, risdiplam or gene-therapy exposure
Nusinersen is an intrathecal disease-modifying option for 5q SMA
EMA authorises Spinraza (nusinersen) for 5q SMA. It is administered intrathecally by an experienced team and requires repeated treatment. For patients with scoliosis, spinal fusion or difficult lumbar anatomy, the center may need procedure planning before confirming how treatment can be delivered.
Risdiplam is an oral systemic treatment option
EMA authorises Evrysdi (risdiplam) for 5q SMA within its labelled patient groups. It is taken orally once daily and can also be administered through a feeding tube when necessary. Choice between therapies is individualized rather than based on convenience alone, especially after prior disease-modifying treatment.
Gene therapy now includes more than one EU-authorised route and age pathway
Onasemnogene abeparvovec has been authorised in the EU as Zolgensma for selected SMA patients and is given as a one-time intravenous infusion under specialist supervision. In 2026, EMA authorised Itvisma, also containing onasemnogene abeparvovec, as a one-time intrathecal gene therapy for eligible people from 2 years of age with inherited SMN1 mutations. These products have different labels, routes, eligibility requirements and monitoring needs; a patient should not assume that prior treatment or age alone determines candidacy.
- Exact product label and molecular eligibility
- Age and clinical status
- Previous SMA disease-modifying therapy
- Spinal anatomy for an intrathecal procedure
- Liver, hematologic and other safety monitoring required by the relevant product
- Center-specific experience and availability
Switching or sequencing SMA therapies needs specialist review
A patient already receiving nusinersen or risdiplam may ask about switching, higher-dose protocols, or gene therapy. Heidelberg continues to participate in SMA studies including treatment-sequencing questions. A second opinion should compare objective motor and respiratory data, tolerability, route feasibility and current evidence rather than assume that the newest therapy is automatically better for an individual patient.
Respiratory care remains essential even with disease-modifying therapy
SMA can weaken respiratory muscles. Comprehensive care can include spirometry or other respiratory assessment, cough-assist strategies, non-invasive ventilation and vaccination/infection-prevention planning. Acute breathing difficulty is an emergency and should be treated locally rather than delayed for international travel.
Swallowing, nutrition and orthopedic care affect long-term outcomes
Bulbar weakness, weight loss or excessive weight gain, contractures and scoliosis can change function and treatment feasibility. Neuromuscular centers coordinate nutrition, speech/swallowing therapy, orthopedics and rehabilitation according to age and disease severity.
- Swallowing and aspiration-risk assessment
- Nutrition and weight trajectory
- Scoliosis and contracture review
- Seating, standing and mobility systems
- Physiotherapy and range-of-motion program
- Occupational therapy and upper-limb support
Motor-function measurements make a second opinion more useful
Specialist centers and SMA registries use standardized motor and functional assessments to follow disease over time. International patients should send serial scores when available together with videos or therapy reports rather than describing change only as 'better' or 'worse'.
Pediatric and adult SMA pathways are related but not identical
Freiburg and Charité document major pediatric neuromuscular programs, while Heidelberg explicitly provides supraregional assessment and second opinions for adults with SMA. Age influences respiratory, orthopedic, reproductive, rehabilitation and treatment-delivery questions, so the inquiry should be routed to the correct pediatric or adult service.
What to send for a German SMA second opinion
The most important documents show molecular eligibility, previous therapy and the current functional baseline.
- SMN1 molecular genetic report and SMN2 copy number if available
- Neuromuscular specialist reports
- Full history of nusinersen, risdiplam or gene therapy, including dates
- Motor-function scores and physiotherapy reports
- Respiratory testing and ventilation/cough-assist information
- Swallowing and nutrition reports
- Spine imaging or surgical history if intrathecal therapy is being considered
- Current medication list
- A specific question: diagnosis confirmation, treatment initiation, switch/sequencing review, route feasibility or multidisciplinary care plan
Official sources
Sources last checked 2026-09-01. Clinical pathways, eligibility and hospital procedures can change; confirm current requirements directly with the treating center.
- Spinraza (nusinersen) – EPAR — European Medicines Agency ↗
- Evrysdi (risdiplam) – EPAR — European Medicines Agency ↗
- Zolgensma (onasemnogene abeparvovec) – EPAR — European Medicines Agency ↗
- Itvisma (onasemnogene abeparvovec) – EPAR — European Medicines Agency ↗
- Neuromuscular outpatient referral information — Heidelberg University Hospital ↗
- Center for neuromuscular diseases in childhood — University Medical Center Freiburg ↗
- Neuromuscular diseases — Charité – Universitätsmedizin Berlin ↗